Method of treating attention deficit disorders with d-threo methylphenidate
DC
First Claim
1. A method of treating at least one of Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder and providing enhanced therapeutic activity, reduced side effects euphoric effect, or potential for drug abuse as compared to racemic threo methylphenidate, said method comprising administering to a human exhibiting symptoms of such disorder therapeutically effective amounts of D-threo methylphenidate or pharmaceutically acceptable salt thereof, substantially free of L-threo methylphenidate, on a daily basis.
1 Assignment
Litigations
0 Petitions
Accused Products
Abstract
Methods for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS while minimizing drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential by administration of d-threo-methylphenidate or pharmaceutically acceptable salts thereof.
191 Citations
4 Claims
- 1. A method of treating at least one of Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder and providing enhanced therapeutic activity, reduced side effects euphoric effect, or potential for drug abuse as compared to racemic threo methylphenidate, said method comprising administering to a human exhibiting symptoms of such disorder therapeutically effective amounts of D-threo methylphenidate or pharmaceutically acceptable salt thereof, substantially free of L-threo methylphenidate, on a daily basis.
Specification
-
- Resources
-
Current AssigneeCelgene Corporation (Bristol-Myers Squibb Company)
-
Original AssigneeCelgene Corporation (Bristol-Myers Squibb Company)
-
InventorsZeitlin, Andrew L., Dariani, Maghsoud M., Stirling, David I.
-
Primary Examiner(s)HENLEY III, RAYMOND J
-
Application NumberUS08/827,230Time in Patent Office790 DaysField of Search514/315US Class Current514/315CPC Class CodesA61K 31/4458 only substituted in positio...
